Identification of Biomarkers Predicting Responsiveness to Rituximab in Follicular Lymphoma
- Correlate immunoglobulin Fc receptor (FcγR) polymorphisms with response, response
duration, and time to resistance in samples from patients with follicular lymphoma (FL)
treated with single-agent rituximab on ECOG-E4402.
- Identify gene expression profiles that correlate with response, response duration, and
time to rituximab resistance in these patients.
- Determine whether the FL microenvironment is predictive of initial response and
duration of response to rituximab.
OUTLINE: DNA and RNA from banked peripheral blood mononuclear cells (PBMCs) and
formalin-fixed paraffin-embedded (FFPE) tumor samples are analyzed for
immunoglobulin-receptor polymorphism, gene expression profile, and follicular lymphoma
microenvironment by real-time PCR, microarray hybridization, and IHC.
PROJECTED ACCRUAL: A total of 259 PBMC samples and 300 FFPE blocks will be accrued for this
Correlation between FcγR polymorphisms and rituximab response, response duration, and time to resistance
Brad S. Kahl, MD
University of Wisconsin, Madison